vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of vTv Therapeutics (NASDAQ:VTVT) from a sell rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.

Other analysts have also recently issued research reports about the company. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. BTIG Research increased their price objective on vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Rodman & Renshaw started coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price objective on the stock. HC Wainwright reduced their price target on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Finally, Weiss Ratings cut shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, vTv Therapeutics has an average rating of “Moderate Buy” and an average target price of $55.83.

vTv Therapeutics Stock Performance

Shares of vTv Therapeutics stock opened at $30.33 on Friday. The stock has a market cap of $119.47 million, a price-to-earnings ratio of -28.61 and a beta of 0.21. The stock has a 50 day moving average price of $32.12 and a 200-day moving average price of $33.82. vTv Therapeutics has a one year low of $19.50 and a one year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08). Sell-side analysts predict that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.